Umsetzung der leitliniengerechten medikamentösen Therapie der chronischen systolischen Herzinsuffizienz bei 200 Patienten mit dilatativer Kardiomyopathie

Es wurde die Umsetzung der Leitlinien im Hinblick auf die medikamentöse Behandlung der chronischen systolischen Herzinsuffizienz bei 200 Patienten mit dilatativer Kardiomyopathie untersucht. Dabei ergab sich bezüglich der Häufigkeiten der leitliniengerecht verordneten Medikamente - im Vergleich zu U...

Full description

Saved in:
Bibliographic Details
Main Author: Schales, Christian
Contributors: Maisch, Bernhard (Prof. Dr.) (Thesis advisor)
Format: Dissertation
Language:German
Published: Philipps-Universität Marburg 2012
Innere Medizin
Subjects:
Online Access:PDF Full Text
Tags: Add Tag
No Tags, Be the first to tag this record!

1. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Rydén L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312-2318.


2. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial -the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-1587.


3. Nicol ED, Fittall B, Roughton M, Cleland JGF, Dargie H, Cowie MR. NHS heart failure survey: a survey of acute heart failure admissions in England, Wales and Northern Ireland. Heart 2008;94:172-177.


4. Zugck C, Franke J, Gelbrich G, Frankenstein L, Scheffold T, Pankuweit S, Duengen HD, Regitz-Zagrosek V, Pieske B, Neumann T, Rauchhaus M, Angermann CE, Katus HA, Ertl GE, Störk S. Implementation of pharmacotherapy guidelines in heart failure: experience from the German Competence Network Heart Failure. Clin Res Cardiol 2011; http://dx.doi.org/10.1007/s00392-011-0388-y.


5. Muntwyler J, Cohen-Solal A, Freemantle N, Eastaugh J, Cleland JG, Follath F. Relation of sex, age and concomitant diseases to drug prescription for heart failure in primary care in Europe. Eur J Heart Fail 2004;6:663-668.


6. Shibata MC, Soneff CM, Tsuyuki RT. Utilization of evidence-based therapies for heart failure in the institutionalized elderly. Eur J Heart Fail 2005;7:1122-1125.


7. Cardiomyopathies: classification, diagnosis, and treatment. Heart Fail Clin 2012;8:53-78.


8. Pankuweit S, Moll R, Baandrup U, Portig I, Hufnagel G, Maisch B. Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Hum Pathol 2003;34:497-503.


9. MERITH-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007.


10. Rutten FH, Grobbee DE, Hoes AW. Differences between general practitioners and cardiologists in diagnosis and management of heart failure: a survey in every-day practice. Eur J Heart Fail 2003;5:337-344.


11. Nohria A, Chen YT, Morton DJ, Walsh R, Vlasses PH, Krumholz HM. Quality of care for patients hospitalized with heart failure at academic medical centers. Am Heart J 1999;137:1028-1034.


12. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994;331:1564-1575.


13. Oertle M, Bal R. Understanding non-adherence in chronic heart failure: a mixed-method case study. Qual Saf Health Care 2010;19:1-5.


14. Shah MR, Granger CB, Bart BA, McMurray JJ, Petrie MC, Michelson EL, Tudor GE, Swedberg K, Stevenson LW, Califf RM, Pfeffer MA. Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. Am J Med 2000;109:489-492.


15. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S, C H A R M Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-766.


16. Remme WJ, McMurray JJV, Hobbs FDR, Cohen-Solal A, Lopez-Sendon J, Boccanelli A, Zannad F, Rauch B, Keukelaar K, Macarie C, Ruzyllo W, Cline C, S H A P E Study Group. Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. Eur Heart J 2008;29:1739-1752.


17. Rakar S, Sinagra G, Lenarda AD, Poletti A, Bussani R, Silvestri F, Camerini F. Epidemiology of dilated cardiomyopathy. A prospective post- mortem study of 5252 necropsies. The Heart Muscle Disease Study Group. Eur Heart J 1997;18:117-123.


18. Maisch B, Ristic AD, Hufnagel G, Funck R, Alter P, Tontsch D, Pankuweit S. Dilated cardiomyopathies as a cause of congestive heart failure. Herz 2002;27:113-134.


19. Maisch B, Richter A, Koelsch S, Alter P, Funck R, Pankuweit S. Management of patients with suspected (peri-)myocarditis and inflammatory dilated cardiomyopathy. Herz 2006;31:881-890.


20. Maisch B, Portig I, Ristic A, Hufnagel G, Pankuweit S. Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus. A status report. Herz 2000;25:200-209.


21. Packer M, Fowler MB, Roecker EB, Coats AJS, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL, Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-2199.


22. Rangaswamy C, Finn JI, Koelling TM. Angiotensin-converting enzyme inhibitor use in elderly patients hospitalized with heart failure and left ventricular systolic dysfunction. Cardiology 2005;103:17-23.


23. Devereux RB, Roman MJ, Paranicas M, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rhoades ER, Rodeheffer RJ, Cowan LD, Howard BV. A population-based assessment of left ventricular systolic dysfunction in middle-aged and older adults: the Strong Heart Study. Am Heart J 2001;141:439-446.


24. Hood S, Taylor S, Roeves A, Crook AM, Tlusty P, Cohen J, Kaddoura S, Hemingway H. Are there age and sex differences in the investigation and treatment of heart failure? A population-based study. Br J Gen Pract 2000;50:559-563.


25. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003;289:871-878.


26. Taylor MR, Carniel E, Mestroni L. Cardiomyopathy, familial dilated. Orphanet J Rare Dis 2006;1:27.


27. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL, Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-1658.


28. Patel JA, Fotis MA. Comparison of treatment of patients with congestive heart failure by cardiologists versus noncardiologists. Am J Health Syst Pharm 2005;62:168-172.


29. Havranek EP, Abrams F, Stevens E, Parker K. Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors. Arch Intern Med 1998;158:2024-2028.


30. Stawicki S, Roik M, Jasik M, Kosior D, Scislo P, Kochanowski J, Dembe K, Steckiewicz R, Karnafel W, Opolski G. Differences between cardiologists and internists in the management of heart failure. Medical guidelines compared with every-day practice. Kardiol Pol 2004;61:431-9; discussion 440-1.


31. Startari U, Taylor MRG, Sinagra G, Lenarda AD, Mestroni L. [Dilated cardiomyopathy: etiology, clinical criteria for diagnosis and screening of the familial form]. Ital Heart J Suppl 2002;3:378-385.


32. Henry WL, Gardin JM, Ware JH. Echocardiographic measurements in normal subjects from infancy to old age. Circulation 1980;62:1054-1061.


33. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.


34. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.


35. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.


36. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.


37. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-2442.


38. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:e391-e479.


39. Mestroni L, Maisch B, McKenna WJ, Schwartz K, Charron P, Rocco C, Tesson F, Richter A, Wilke A, Komajda M. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J 1999;20:93-102.


40. Costantini O, Huck K, Carlson MD, Boyd K, Buchter CM, Raiz P, Cooper GS. Impact of a guideline-based disease management team on outcomes of hospitalized patients with congestive heart failure. Arch Intern Med 2001;161:177-82.


41. Reibis R, Dovifat C, Dissmann R, Ehrlich B, Schulz S, Stolze K, Wegscheider K, Völler H. Implementation of evidence-based therapy in patients with systolic heart failure from 1998-2000. Clin Res Cardiol 2006;95:154-161.


42. Maisch B, Richter A, Sandmöller A, Portig I, Pankuweit S, B M B F-Heart Failure Network. Inflammatory dilated cardiomyopathy (DCMI). Herz 2005;30:535-544.


43. Yancy CW, Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Mehra MR, O'Connor CM, Reynolds D, Walsh MN. Influence of patient age and sex on delivery of guideline- recommended heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Am Heart J 2009;157:754-62.e2.


44. Insights from the IMPACT RECO survey. Eur J Heart Fail 2007;9:1205- 1211.


45. Hoppe UC, Erdmann E, Kommission Klinische Kardiologie der Deutschen Gesellschaft für Kardiologie -Herz-und Kreislaufforschung eV. Leitlinien zur Therapie der chronischen Herzinsuffizienz. Z Kardiol 2001;90:218-237.


46. Ollenschläger G, Kirchner H, Fiene M. Leitlinien in der Medizin -scheitern sie an der praktischen Umsetzung? Internist (Berl) 2001;42:473-4, 477-83.


47. Guillo P, Mansourati J, Maheu B, Etienne Y, Provost K, Simon O, Blanc JJ. Long-term prognosis in patients with alcoholic cardiomyopathy and severe heart failure after total abstinence. Am J Cardiol 1997;79:1276- 1278.


48. Setoguchi S, Levin R, Winkelmayer WC. Long-term trends of angiotensin- converting enzyme inhibitor and angiotensin-receptor blocker use after heart failure hospitalization in community-dwelling seniors. Int J Cardiol 2008;125:172-177.


49. Maison P, Cunin P, Hemery F, Fric F, Elie N, Del'volgo A, Dubois-Randé JL, Hittinger L, Macquin-Mavier I. Utilisation of medications recommended for chronic heart failure and the relationship with annual hospitalisation duration in patients over 75 years of age. A pharmacoepidemiological study. Eur J Clin Pharmacol 2005;61:445-451.


50. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson JT, Meier P, Ronan NS, Shapiro PA, Lazar RM, Miller LW, Gupta L, Frazier OH, Desvigne-Nickens P, Oz MC, Poirier VL, of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group RE. Long-term mechanical left ventricular assistance for end- stage heart failure. N Engl J Med 2001;345:1435-1443.


51. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996;93:841-842.


52. Vaccarino V, Chen YT, Wang Y, Radford MJ, Krumholz HM. Sex differences in the clinical care and outcomes of congestive heart failure in the elderly. Am Heart J 1999;138:835-842.


53. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.


54. Hufnagel G, Pankuweit S, Richter A, Schönian U, Maisch B. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). First epidemiological results. Herz 2000;25:279- 285.


55. Hufnagel G, Pankuweit S, Maisch B. [Therapy of dilated cardiomyopathies with and without inflammation]. Med Klin (Munich) 1998;93:240-251.


56. Association and American College of Cardiology and European Society of Cardiology. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 2007;116:2216-2233.


57. Korewicki J, Lévy S, Linde C, Lopez-Sendon JL, Nieminen MS, Piérard L, Remme WJ, Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-1140.


58. de la Porte PWFBA, Lok DJA, van Veldhuisen DJ, van Wijngaarden J, Cornel JH, Zuithoff NPA, Badings E, Hoes AW. Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventer-Alkmaar heart failure study. Heart 2007;93:819-825.


59. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ 1996;312:71- 72.


60. Rathore SS, Foody JM, Wang Y, Herrin J, Masoudi FA, Havranek EP, Ordin DL, Krumholz HM. Sex, quality of care, and outcomes of elderly patients hospitalized with heart failure: findings from the National Heart Failure Project. Am Heart J 2005;149:121-128.


61. Weil E, Tu JV. Quality of congestive heart failure treatment at a Canadian teaching hospital. CMAJ 2001;165:284-287.